Pharmacologic considerations in the neonate with congenital heart disease.
Advances in knowledge about the developing cardiovascular system and compensatory physiologic changes that occur in infants with congenital heart disease have led to new approaches in the management of cardiac failure and arrhythmias. Information about the pharmacologic effects, pharmacokinetics, and pharmacodynamics of newer agents used in the management of congenital heart disease have led to more appropriate use of these medications to prolong survival and improve outcomes.
Calligaro
I L
IL
Department of Pharmacy Practice, Temple University School of Pharmacy, Philadelphia, Pennsylvania, USA. caligaro@astro.temple.edu
Burman
C A
CA
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000209:etiology* / Q000401:mortality / Q000503:physiopathology; D002316:Cardiotonic Agents / Q000494:pharmacology / Q000627:therapeutic use; D006330:Heart Defects, Congenital / Q000150:complications*; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology* / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D007231:Infant, Newborn; D016019:Survival Analysis; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D002316:Cardiotonic Agents